Zacks: Brokerages Expect PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Will Announce Quarterly Sales of $5.83 Million

Wall Street analysts expect PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) to post sales of $5.83 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $9.17 million. The firm is […]

Related Keywords

,Morgan Stanley ,Phasebio Pharmaceuticals Inc ,Goldman Sachs Group Inc ,Phasebio Pharmaceuticals Get Rating ,Zacks Investment Research ,Nasdaq ,Needham Company ,Cubist Systematic Strategies ,Phasebio Pharmaceuticals ,Citadel Advisors ,Millennium Management ,Wall Street ,Get Rating ,Phasebio Pharmaceutical ,Bio Pharmaceuticals ,Sachs Group ,Systematic Strategies ,Nasdaq Phas ,Kephas ,Medical ,Ratings ,Consensus ,